Key Points
- Oramed CFO Avraham Gabay sold 20,000 shares at an average price of $4.51, generating $90,200. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, leaving him with 861,076 shares.
- ORMP opened at $4.49 and has traded between $2.09 and $5.47 over the past year. The company recently reported a quarterly loss of $0.09 per share, missing the consensus estimate of $0.43.
- Analyst sentiment remains mixed, with a consensus “Hold” rating, while hedge funds and institutional investors own approximately 12.73% of the company.
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) CFO Avraham Gabay sold 20,000 shares of the firm's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $90,200.00. Following the transaction, the chief financial officer owned 861,076 shares in the company, valued at approximately $3,883,452.76. This represents a 2.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oramed Pharmaceuticals Price Performance
ORMP stock opened at $4.49 on Friday. Oramed Pharmaceuticals Inc. has a 1-year low of $2.09 and a 1-year high of $5.47. The business has a 50-day moving average price of $4.64 and a 200 day moving average price of $4.19. The company has a market capitalization of $186.77 million, a P/E ratio of 1.09 and a beta of 1.29.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.52). On average, analysts anticipate that Oramed Pharmaceuticals Inc. will post 1.47 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on ORMP. Wall Street Zen raised shares of Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Weiss Ratings reissued a "hold (c+)" rating on shares of Oramed Pharmaceuticals in a report on Tuesday, September 8th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of "Hold".
View Our Latest Stock Analysis on ORMP
Institutional Investors Weigh In On Oramed Pharmaceuticals
Hedge funds have recently made changes to their positions in the stock. SB Capital Management Inc bought a new stake in Oramed Pharmaceuticals during the fourth quarter valued at about $5,415,000. Dimensional Fund Advisors LP grew its stake in Oramed Pharmaceuticals by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company's stock valued at $538,000 after purchasing an additional 7,738 shares during the last quarter. Ritholtz Wealth Management bought a new position in Oramed Pharmaceuticals in the first quarter worth about $529,000. Bank of America Corp DE raised its holdings in Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company's stock worth $497,000 after purchasing an additional 3,909 shares in the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new stake in shares of Oramed Pharmaceuticals during the first quarter valued at about $331,000. 12.73% of the stock is currently owned by hedge funds and other institutional investors.
Oramed Pharmaceuticals Company Profile
(
Get Free Report)
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) is a biopharmaceutical company focused on developing orally administered therapies that are traditionally delivered by injection. The company's technology is designed to protect therapeutic proteins and peptides as they pass through the digestive system and facilitate their absorption in the body.
Oramed's lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) analog candidate.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
